AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Key Points:
- Graft Polymer and Awakn Life Sciences have partnered with the University of Nottingham to study the potential of an aminoindane new chemical entity (NCE) in enhancing social cognition for trauma-related disorders.
- Led by Dr. Madeleine King, the research will employ rodent models and is expected to yield results by the end of 2024.
- The study aims to contribute to the development of next-generation therapeutics for PTSD, which affects millions in the U.S. and Europe.
Graft Polymer (UK) Plc (LSE:GPL), an innovative biotechnology firm dedicated to developing therapeutics for mental health disorders, has announced a new research agreement between its partner, Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF), and the University of Nottingham. This collaborative research will evaluate the potential of the aminoindane new chemical entity (NCE) co-lead series developed by Graft Polymer and Awakn to enhance social cognition and pro-social behaviors. This research represents a crucial step toward creating a new class of medications aimed at treating trauma-related disorders, including Post-Traumatic Stress Disorder (PTSD).
The study will be spearheaded by Dr. Madeleine King, an Assistant Professor in the Faculty of Medicine & Health Sciences at the University of Nottingham, renowned for its advanced neuroscience research. Dr. King, who has over 20 years of experience in behavioral neuroscience with a focus on psychiatric disorders, will lead the research, which will employ the Social Transmission of Food Preferences (STFP) test in rodent models. The research is slated to take place over a two-month period, with results anticipated by the end of 2024.
This in vivo research marks a significant advancement in Graft Polymer’s NCE program, which is being developed under a collaboration agreement with Awakn. The program aims to create next-generation therapeutics for mental health issues, particularly PTSD, a disorder that impacts more than 13 million adults in the United States and approximately 20 million individuals across the U.S., UK, and Europe.
As the demand for effective treatments for mental health disorders continues to grow, this research highlights the commitment of Graft Polymer and Awakn to pioneer innovative solutions that could improve the quality of life for those affected by trauma-related conditions.
